Previously, our group found that IHC scoring of CD38+ and CD38+CD68+ cell densities in the tumor microenvironment predicted HCC patient responses to anti-PD-1/anti-PD-L1 ICB (24). This evidence concerns the gene PDCD1 and neoplasm.